Bridging the antiviral gap: A BAC-based non-infectious SARS-CoV-2 replicon reveals potent antisense gapmers
Molecular Therapy: Nucleic Acids
· Elsevier
Аннотация
Publication date: 8 December 2026 Source: Molecular Therapy Nucleic Acids, Volume 37, Issue 4 Author(s): Agnieszka Ruszkowska, Agnieszka Baliga-Gil, Julita Piasecka, Maria Ciechanowska, Ryszard Kierzek, Elzbieta Kierzek
Читать у издателя →
Цитировать
Получайте новые статьи по теме «Поиск и разработка лекарств»
Подписка, поиск по ключевым словам и избранное — в Telegram-боте Articlium.
Открыть в Telegram
Цитирование
✕
ГОСТ
APA
MLA
BibTeX
Bridging the antiviral gap: A BAC-based non-infectious SARS-CoV-2 replicon reveals potent antisense gapmers. // Molecular Therapy: Nucleic Acids. – URL: https://www.sciencedirect.com/science/article/pii/S2162253126002696?dgcid=rss_sd_all
Bridging the antiviral gap: A BAC-based non-infectious SARS-CoV-2 replicon reveals potent antisense gapmers. Molecular Therapy: Nucleic Acids. https://www.sciencedirect.com/science/article/pii/S2162253126002696?dgcid=rss_sd_all
“Bridging the antiviral gap: A BAC-based non-infectious SARS-CoV-2 replicon reveals potent antisense gapmers.” Molecular Therapy: Nucleic Acids.
@article{article59362,
title = {Bridging the antiviral gap: A BAC-based non-infectious SARS-CoV-2 replicon reveals potent antisense gapmers},
journal = {Molecular Therapy: Nucleic Acids},
url = {https://www.sciencedirect.com/science/article/pii/S2162253126002696?dgcid=rss_sd_all}
}